Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued [GID-TAG330]

  2. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

  3. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

  4. Venous leg ulcers - new treatments [ID394]

    Discontinued [GID-TAG370]

  5. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]

  6. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]

  7. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued [GID-TAG396]

  8. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

  9. Thrombophilia [ID393]

    Discontinued [GID-TAG374]

  10. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

  11. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

  12. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

  13. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

  14. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

  15. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]